Arcutis Biotherapeutics, Inc. (ARQT)

NMS – Real Time Price. Currency in USD

21.69

+1.00 (4.83%)

At close: May 13, 2026, 4:00 PM EDT

21.61

-0.08 (-0.37%)

After-hours: May 13, 2026, 5:14 PM EDT

Stock details

Previous close: 21.24$
Day's range: 20.94 - 21.72$
52-week range: 12.72 - 31.77$
Volume: 3 327 291
Average volume: 2 088 464
Beta: 0.84
EPS (TTM): -0.02
PE ratio (TTM): N/A
Forward P/E: 106.87
Market cap: 2 656 770 874
Shares outstanding: 125 083 374
Dividend yield: N/A
Next earnings date: 2026-07-30
Sector: Healthcare
Industry: Biotechnology

About the company

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective che... read more

CEO: Todd Watanabe
Country: United States
IPO Date: 2020-01-31
Employees: 354
Fiscal Year End: January - December
Website: https://www.arcutis.com

Revenue Breakdown

Dermatological Treatments / 100.00%

News

No Data

There are no news for this stock.

Chart: ARQT

Loading Chart...

Overall Score

4.2 / 1042%

Financial Strength

Profitability

Effectiveness

1.3

Growth

7.3

Forecast

Valuation

2.8

Dividend

Economic Moat

Octagon View

Strength & Weakness

Total debt $114.7M significantly exceeds cash reserves ($35.1M), raising financial stability concerns

Total current assets $438.1M exceed Total current liabilities $163.2M, highlighting excellent liquidity

Debt-to-equity ratio (0.6) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (-2.1x) is dangerously low, suggesting debt repayment risks

The company generates positive free cash flow $2.2M, supporting its financial health

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.68	6.05	10
Quick ratio	2.46	5.63	10
Debt to Equity	0.60	0.30	7.0
Debt to Assets	0.25	1.04	7.0
Interest coverage	-2.08	-16.91	1.0
Weighted average score			7.0

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	4M	60M	197M	376M	416M
Gross Profit	2M	53M	177M	339M	378M
Operating Income	-302M	-241M	-128M	-12M	3M
Net Income	-311M	-262M	-140M	-16M	-2M
EBITDA	-300M	-239M	-126M	-7M	6M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	90.72	-11.73	10
Operating margin %	-8.62	-24.60	1.0
Net margin %	-10.72	-172.20	1.0
EBITDA margin %	-8.09	-201.27	1.0
Cash flow margin %	2.12	-156.39	2.0
Weighted average score			3.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-9.77	-57.97	1.0
ROE	-24.06	-63.56	1.0
ROIC	-13.04	-42.57	1.0
ROCE	0.07	-71.10	2.0
Weighted average score			1.3

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	44.21	132.69	10
Next quarter	30.04	39.58	10
Current year	32.13	252.88	10
Next year	29.84	437.74	10
Weighted average score			10

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-18.6	-164.92	-169.22	-91.44	1.0
Y/Y	60.07	54.93	55	107.23	10
3y average	612.72	50.29	63.77	51.03	10
5y average	767.23	9.58	29.19	10.25	8.3
Weighted average score					7.3

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	N/A	-5.25	1.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	6.52	64.66	6.4
P/B	13.96	2.96	2.8
Weighted average score			2.8

DCF Model

DCF Model PeriodN/A

Discount rateN/A

Perpetual growth rateN/A

Revenue 5 year CAGRN/A

FCF 5 year CAGRN/A

Fair valueN/A

Stock price21.24$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$1

UndervaluedStock priceOvervalued

$21.24

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Todd Watanabe

Country

United States

IPO Date

2020-01-31

Employees

354

Fiscal Year End

January - December

Website

https://www.arcutis.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.68

6.05

Quick ratio

2.46

5.63

Debt to Equity

0.60

0.30

7.0

Debt to Assets

0.25

1.04

7.0

Interest coverage

-2.08

-16.91

1.0

Weighted average score

7.0

METRIC

2022

2023

2024

2025

TTM

Total Revenue

60M

197M

376M

416M

Gross Profit

53M

177M

339M

378M

Operating Income

-302M

-241M

-128M

-12M

Net Income

-311M

-262M

-140M

-16M

-2M

EBITDA

-300M

-239M

-126M

-7M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

90.72

-11.73

Operating margin %

-8.62

-24.60

1.0

Net margin %

-10.72

-172.20

1.0

EBITDA margin %

-8.09

-201.27

1.0

Cash flow margin %

2.12

-156.39

2.0

Weighted average score

3.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-9.77

-57.97

1.0

ROE

-24.06

-63.56

1.0

ROIC

-13.04

-42.57

1.0

ROCE

0.07

-71.10

2.0

Weighted average score

1.3

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

44.21

132.69

Next quarter

30.04

39.58

Current year

32.13

252.88

Next year

29.84

437.74

Weighted average score

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-18.6

-164.92

-169.22

-91.44

1.0

Y/Y

60.07

54.93

107.23

3y average

612.72

50.29

63.77

51.03

5y average

767.23

9.58

29.19

10.25

8.3

Weighted average score

7.3

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

N/A

-5.25

1.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

6.52

64.66

6.4

P/B

13.96

2.96

2.8

Weighted average score

2.8

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Arcutis Biotherapeutics, Inc. (ARQT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Arcutis Biotherapeutics, Inc. (ARQT)

Stock details

About the company

Revenue Breakdown

News

Chart: ARQT

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$21.24

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: ARQT

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$21.24

Economic Moat